AML patients with mutated IKZF1 was usually associated with aberration in RUNX1, GATA2, KRAS, KIT, SF3B1, and ETV6. IKZF1 mutation could be an independent marker of adverse risk regarding complete remission rate, event-free, relapse-free, and overall survival (101). The gene discussed is IKZF1; the disease is acute myeloid leukemia.